Results 1 to 10 of about 373,608 (350)

Can angiogenesis inhibitor therapy cause changes in imaging features of hepatic hemangioma- Initial study [PDF]

Frontiers in Oncology, 2023
BackgroundTo observe whether anti-angiogenesis therapy can induce changes in size and enhancement characteristics of hepatic hemangioma.Method133 patients with hepatic hemangioma lesions were analyzed and classified into a Bevacizumab group (n=65) and ...
Tang Liu, Wenxue Pan, Shengyuan Lai, Jiawen Luo   +3 more
doaj   +2 more sources

First‐line immunotherapy or angiogenesis inhibitor combined with chemotherapy for advanced non‐small cell lung cancer with EGFR exon 20 insertions: Real‐world evidence from China [PDF]

Cancer Medicine, 2023
Background Currently, survival benefit of immunotherapy in advanced non‐small cell lung cancer (NSCLC) with EGFR exon 20 insertions (ex20ins) is controversial, though it generally indicates poor response and activity.
Guangjian Yang, Yaning Yang, Runze Liu, Weihua Li, Haiyan Xu, Xuezhi Hao, Junling Li, Shuyang Zhang, Fei Xu, Siyu Lei, Yan Wang   +10 more
doaj   +2 more sources

Case report: Pathological complete response to perioperative treatment of radiotherapy combined with angiogenesis inhibitor in a patient with pleomorphic liposarcoma [PDF]

Frontiers in Oncology, 2023
BackgroundLiposarcomas (LPS) are mesenchymal malignancies with four principal subtypes presenting distinct molecular and clinical features. Pleomorphic liposarcoma (PLPS) is one of the rarest and most aggressive subtypes of LPS.
Chenlu Zhang, Wenshuai Liu, Binliang Wang, Na Zhu, Xi Guo, Zhiming Wang, Rongyuan Zhuang, Yang You, Yong Zhang, Hanxing Tong, Weiqi Lu, Yuhong Zhou   +11 more
doaj   +2 more sources

Impact of angiogenesis inhibitor eligibility on the prognosis of patients with non‐small cell lung cancer harboring EGFR mutation [PDF]

Cancer Medicine, 2021
Background Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR‐TKIs) are currently the primary treatment option for patients with EGFR‐mutant non‐small cell lung cancer (NSCLC).
Hiroaki Kodama, Hirotsugu Kenmotsu, Takanori Kawabata, Akifumi Notsu, Michitoshi Yabe, Naoya Nishioka, Eriko Miyawaki, Taichi Miyawaki, Nobuaki Mamesaya, Haruki Kobayashi, Shota Omori, Kazushige Wakuda, Akira Ono, Tateaki Naito, Haruyasu Murakami, Toshiaki Takahashi   +15 more
doaj   +2 more sources

Host angiogenic reprogramming by Echinococcus multilocularis protoscoleces protein via PDGFR/PI3K/AKT cascade [PDF]

Frontiers in Microbiology
BackgroundAlveolar echinococcosis (AE) is a globally present zoonotic disease caused by Echinococcus multilocularis (E. multilocularis) infection, characterized by the formation of tumor-like growths primarily in the liver, with the potential to spread ...
Xiaojuan Bi, Ning Yang, Ying Ke, Junlong Xue, Xue Zhang, Hui Liu, Jin Chu, Liang Li, Yingmei Shao, Guodong Lü, Tuerganaili Aji, Renyong Lin   +11 more
doaj   +2 more sources

Major Adverse Cardiovascular Events in Angiogenesis Inhibitor‐Based Cancer Therapy: A Systematic Review and Meta‐Analysis [PDF]

Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease
Background Angiogenesis inhibitors (AIs) are effective in cancer therapy due to their ability to suppress tumor vasculature. However, these agents are associated with significant cardiovascular toxicities, including hypertension, thrombosis, and heart ...
Yuxuan Tao, Weilu Cui, Wenyuan Song, Haotian Xu, Jing Zeng, Haixia Li   +5 more
doaj   +2 more sources

On-Target Side Effects of Targeted Therapeutics of Cancer

Pathology and Oncology Research, 2022
The concept of precision medicine is based on the identification of hallmarks of cancer to exploit them as drug targets. The basic idea was that in this way the therapeutic modalities will be more effective and the side effects will be less.
József Tímár, Andrea Uhlyarik
doaj   +1 more source

Trisubstituted pyrazolopyrimidines as novel angiogenesis inhibitors. [PDF]

, 2013
Current inhibitors of angiogenesis comprise either therapeutic antibodies (e.g. bevacicumab binding to VEGF-A) or small molecular inhibitors of receptor tyrosin kinases like e.g. sunitinib, which inhibits PDGFR and VEGFR.
Fürst, Robert, Gucký, Tomáš, Havlíček, Libor, Krystof, Vladimir, Liebl, Johanna, Strnad, Miroslav, Vollmar, Angelika M., Weitensteiner, Sabine B., Zahler, Stefan   +8 more
core   +13 more sources

The first Russian register of patients with neovascular age-related macular degeneration: a real-world clinical study

Российский офтальмологический журнал, 2023
Purpose: data analysis of Russia’s first register of neovascular age-related macular degeneration (nAMD) — a web-based system for clinical monitoring of nAMD patients designed to collect and accumulate the data on such patients, their demographic, social
V. V. Neroev, O. V. Zaytseva, V. A. Petrakovskaya, M. A. Trifonova, E. I. Ganeeva   +4 more
doaj   +1 more source

Targeted therapy and immunotherapy: Diamonds in the rough in the treatment of epithelial ovarian cancer

Frontiers in Pharmacology, 2023
Currently, for ovarian cancer, which has the highest mortality rate among all gynecological cancers, the standard treatment protocol is initial tumor cytoreductive surgery followed by platinum-based combination chemotherapy.
Xu Huang, Xu Huang, Xiao-Yu Li, Xiao-Yu Li, Wu-Lin Shan, Yao Chen, Qi Zhu, Bai-Rong Xia   +7 more
doaj   +1 more source